Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality

• Published in: BJU international 2017-12, Vol.120 (6), p.799-807
• Main Authors: Greiman, Alyssa K., Rosoff, James S., Prasad, Sandip M.
• Format: Article
• Language: English
• Subjects: Age; Bladder; Bladder cancer; Cancer; Databases, Factual; Developed Countries; epidemiology; Female; Global Health; Humans; Incidence; Kidney cancer; Male; Mortality; Prostate; Prostate cancer; Prostatic Neoplasms - epidemiology; Testicular cancer; Testicular Neoplasms - epidemiology; testis cancer; Urinary bladder; Urologic Neoplasms - epidemiology
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.13875

Objectives To describe contemporary worldwide age‐standardized incidence and mortality rates for bladder, kidney, prostate and testis cancer and their association with development. Materials and Methods We obtained gender‐specific, age‐standardized incidence and mortality rates for 184 countries and 16 major world regions from the GLOBOCAN 2012 database. We compared the mortality‐to‐incidence ratios (MIRs) at national and regional levels in males and females, and assessed the association with socio‐economic development using the 2014 United Nations Human Development Index (HDI). Results Age‐standardized incidence rates were 2.9 (bladder) to 7.4 (testis) times higher for genitourinary malignancies in more developed countries compared with less developed countries. Age‐standardized mortality rates were 1.5–2.2 times higher in more vs less developed countries for prostate, bladder and kidney cancer, with no variation in mortality rates observed in testis cancer. There was a strong inverse relationship between HDI and MIR in testis (regression coefficient 1.65, R2 = 0.78), prostate (regression coefficient −1.56, R2 = 0.85), kidney (regression coefficient −1.34, R2 = 0.74), and bladder cancer (regression coefficient −1.01, R2 = 0.80). Conclusion While incidence and mortality rates for genitourinary cancers vary widely throughout the world, the MIR is highest in less developed countries for all four major genitourinary malignancies. Further research is needed to understand whether differences in comorbidities, exposures, time to diagnosis, access to healthcare, diagnostic techniques or treatment options explain the observed inequalities in genitourinary cancer outcomes.